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Abstract 
Experimental autoimmune encephalomyelitis (EAE) was induced in Lewis rats by inoculation with 
myelin basic protein (MBP) and adjuvants. Rats were treated with second daily injections of saline or 
cyclosporin A (CsA) from the day of inoculation. Saline-treated rats had an acute episode of disease 
followed by clinical recovery. Rats treated with CsA 16 or 32 mg/kg had minimal signs of EAE at the 
usual time after inoculation, but developed signs of disease after treatment was ceased. Rats treated 
with CsA 8 mg/kg had a delayed first episode of disease and then developed a relapsing or a chronic 
persistent course of disease. CsA 4 mg/kg delayed the onset of disease. To study the effects of CsA on 
the inflammatory infiltrate, cells were extracted from the spinal cords of rats with EAE, 16 h after a 
single injection of CsA or saline. Extracted cells were labelled with antibodies to T cells, CD11b/c 
(macrophages/microglia), CD95 (Fas) and Fas ligand. CsA 4 mg/kg did not alter the composition of the 
inflammatory infiltrate. Treatment with higher single doses of CsA caused a dose-dependent decline in 
the percentage of T cell receptor (TCR) + cells in the inflammatory infiltrate. All doses of CsA 
caused a significant increase in the number and percentage of cells that were apoptotic. CsA treatment 
caused an increase in the percentages of CD5+ and TCR + cells that were apoptotic. There was a 
decline in the percentage of apoptotic T cells that were V 8.2+, compared to the percentage of non-
apoptotic T cells that were V 8.2+, in CsA treated rats compared to saline-treated controls. This 
suggests that, while CsA treatment caused a non-specific increase in the overall level of T cell 
apoptosis in the spinal cord, it abrogated the selective apoptosis of V 8.2+ encephalitogenic T cells 
that normally occurs during spontaneous recovery from acute EAE.  
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1. Introduction 
Cyclosporin A (CsA) is a cyclic peptide with immunomodulatory properties. CsA acts within the cell 
by binding to cyclophilin, an immunophilin. This results in inactivation of calcineurin, and suppression 
of transcription of genes, including those for cytokines and cytokine receptors (Flanagan et al., 1991). 
Immunophilins also have neuroprotective abilities (Sabatini et al., 1997). CsA is used as an 
immunosuppressive agent in organ transplantation and in the treatment of autoimmune diseases. In 
multiple sclerosis, CsA treatment has been of modest benefit (Multiple Sclerosis Study Group, 1990). 
In some situations, CsA can provoke autoimmune disease. One example of CsA-induced autoimmunity 
is the graft versus host disease that occurs in CsA-treated animals after syngeneic bone marrow 
transplantation (Hess et al., 1994). CsA in high doses suppresses clinical signs of experimental 
autoimmune encephalomyelitis (EAE) (Bolton et al., 1982; Polman et al., 1988) which is an animal 
model of multiple sclerosis. In Lewis rats, treatment with low-dose CsA (4 mg/kg) converts EAE 
induced by inoculation with guinea pig spinal cord from an acute to a chronic relapsing disease 
(Polman et al., 1988; Pender et al., 1990; McCombe et al., 1994). The relapsing disease produced by 
treatment with CsA may result from the suppression of the immunoregulatory mechanisms that 
normally prevent further episodes of disease. In EAE, such regulatory mechanisms may include 
suppressor cells (Karpus et al., 1992), downregulatory cytokines, and apoptosis of T cells in the central 
nervous system (CNS) (Pender et al., 1991 and Pender et al., 1992; Schmied et al., 1993; Tabi et al., 
1994 and Tabi et al., 1995; McCombe et al., 1996a). 
The present study was performed in two parts. Firstly, we assessed the effects of CsA treatment on the 
clinical course of EAE induced by inoculation with myelin basic protein (MBP), to determine whether 
this is similar to the effects of CsA on EAE induced by inoculation with whole spinal cord. Secondly, 
we studied the effects of a single dose of CsA on the inflammatory infiltrate extracted from the spinal 
cord of rats with EAE. Because apoptosis is involved in the spontaneous recovery of rats from acute 
EAE, we also assessed the effects of CsA on apoptosis of inflammatory cells in the spinal cord in EAE. 
2. Methods 
2.1. Induction of EAE 
Male Lewis rats (JC strain), aged 8–10 weeks, were obtained from the Central Animal Breeding House 
of The University of Queensland. MBP was prepared from guinea pig brains by the method of Deibler 
et al. (1972). MBP in 0.9% saline was emulsified in an equal volume of incomplete Freund's adjuvant 
containing 4 mg/ml Mycobacterium butyricum. On day 0, rats were inoculated in one hind footpad 
with 0.1 ml emulsion. The total dose of MBP was 50 µg/rat. We assessed weakness of the tail, 
hindlimbs and forelimbs. The degree of weakness of each region was separately graded on a scale of 0 
(no weakness) to 4 (total paralysis) as previously described (Pender, 1986). The scores from each 
region were added together to give a total clinical score (maximum total clinical score=12). 
2.2. CsA treatment 
For studies of the effects of CsA treatment on the clinical course of EAE, rats were given 
intraperitoneal injections of saline or CsA every second day, commencing on the day of inoculation, for 
periods of 21–42 days. For studies of the effects of CsA on the cells extracted from the spinal cord, rats 
were given a single injection of CsA, at an interval of 16 h before sacrifice on either day 14 or day 15 
after inoculation. 
2.3. Extraction of cells from spinal cord 
As described previously (McCombe et al., 1996b), cells were isolated from the spinal cords of 
anaesthetized rats perfused with ice-cold saline. The spinal cord was removed by insufflation, weighed, 
and a single cell suspension in ice-cold RPMI 1640 containing 1% foetal calf serum (FCS) was 
prepared. The cell suspension was mixed with isotonic Percoll (Percoll: Hank's balanced salt solution 
9:1) in a 3:2 ratio (density 1.052) in 50 ml centrifuge tubes and centrifuged for 25 min at 640×g at 4°C. 
The myelin layer and supernatant were discarded, while the last 9 ml supernatant and the cell pellet 
were retained. The cell pellet was resuspended, transferred to a conical 10 ml centrifuge tube, underlaid 
with 1 ml Ficoll and centrifuged for 20 min at 600×g at 4°C. Cells were harvested from the interface. 
2.4. Antibodies 
We used the following primary antibodies: OX19 (Dallman et al., 1984) (CD5); R73 (Hünig et al., 
1989) (TCR ); R78 (Torres Nagel et al., 1993) which labels V 8.2+ T cells (the predominant 
encephalitogenic cells in MBP-EAE) (Imrich et al., 1995); OX42, which labels CD11b/c+ cells 
(macrophages and microglia); and rabbit polyclonal antibodies specific for rat CD95 (Fas) (Santa Cruz) 
and rat CD95 (Fas) ligand (Santa Cruz Biotechnology). The secondary antibodies were fluorescein 
isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG F(ab′)2 (STAR 41) (Serotec) and FITC-
conjugated goat anti-rabbit IgG (ab′)2 (Rockland, Gilbertsville, PA). 
2.5. Labelling of cells and flow cytometric analysis 
Cells were labelled for flow cytometric analysis, using our previously described methods (McCombe et 
al., 1996b). Aliquots of 105–106 cells were washed with a 1:1 solution of serum in phosphate-buffered 
saline (PBS) containing 1% FCS and 0.1% sodium azide, then incubated with primary antibodies in 
PBS/azide for 30 min at 4°C. Samples were washed and incubated with secondary antibody for 30 min 
at 4°C in the dark. Cells were washed twice with PBS and were resuspended in 1 ml of ice-cold 50% 
ethanol and fixed overnight at 4°C. The following day, the cells were washed in PBS. The cell pellets 
were resuspended in an appropriate volume (100–300 l) of propidium iodide (PI)-staining solution 
(freshly prepared by diluting stock solution [5 mg/ml RNase/250 g/ml PI in 0.1 M PBS), pH 7.4/0.1 
mM EDTA] 1:4 with PBS/azide). Samples were kept on ice, in the dark, and analyzed using a Becton 
Dickinson FACScan. Flow cytometric data were analyzed using Lysis II Software (Becton Dickinson). 
The percentages of antibody-positive cells were determined from histograms of FITC fluorescence 
intensity. Background fluorescence, obtained by labelling the cells with isotype-control antibodies and 
FITC-conjugated secondary antibody, was subtracted from the test values. To analyze the proportions 
of cells undergoing apoptosis, or in G1/G0 or S/G2/M phase, histograms of PI fluorescence were 
obtained, as described by Telford et al. (1991). Apoptotic events were defined as those having lower 
fluorescence than the sharply defined G0/G1 peak (White et al., 1998b). Events with higher 
fluorescence than this peak were defined as being in S/G2/M phase. Events with a low level of red (PI) 
fluorescence were not collected. Electronic compensation for two-colour analysis ensured unchanged 
FITC distribution following PI labelling of DNA. 
2.6. Statistical analysis 
Statistical analysis was carried out using analysis of variance (ANOVA) with Sigmastat 2.0 (Jandel 
Scientific). Results for observations at different doses of CsA were then compared with results for 
saline by the Tukey test. 
3. Results 
3.1. Effect of second daily CsA treatment on the clinical course of EAE 
A summary of the effects of CsA treatment is shown in Table 1, and examples of the clinical course of 
individual rats are shown in Fig. 1. Rats treated with saline for 21–42 days had a first episode of 
disease commencing around day 10. Some saline-treated rats had a second episode of disease, but none 
had a third episode of disease or chronic disease. Rats treated with CsA 4 mg/kg had a clinical course 
of disease similar to that of saline-treated rats, except that the onset of signs of disease was delayed. 
Second daily treatment with CsA 8 mg/kg caused a mild delay of the first episode of disease and then 
multiple relapses or a chronic persistent course of disease in 50% of the rats. In this group, rats in the 
first episode of disease generally had weakness of the tail and hindlimbs, while in the later episodes of 
disease there was weakness of the tail and forelimbs, but not the hindlimbs. Second daily treatment 
with CsA 16 or 32 mg/kg prevented the development of disease during the course of treatment, 
although the rats later developed signs of disease after CsA treatment was ceased.  
 
 Fig. 1. Effects of CsA treatment on the clinical course of disease, showing the clinical course of representative rats 
treated with second daily injections of saline, CsA 8, 16 and 32 mg/kg from the day of inoculation until day 22. 
The rat treated with saline had a single episode of disease, the rat treated with CsA 8 mg/kg had a delayed onset of 
disease followed by relapses, while the rats treated with CsA 16 and 32 mg/kg failed to develop disease until 
treatment had been ceased. 
3.2. Effect of a single dose of CsA on spinal cord inflammatory cells 
The details of rats in the study are shown in Table 2. A single dose of CsA had no significant effect on 
the severity of disease or on the number of cells extracted from the spinal cord, compared to treatment 
with saline. The proportions and numbers of cells of different types are shown in Table 3. Treatment 
with CsA 4 mg/kg or 8 mg/kg had no significant effect on the composition of the cell population. The 
highest dose (CsA 32 mg/kg) caused a significant decline in the percentages of TCR + lymphocytes 
and V 8.2+ cells and an increase in the percentage of CD11b/c+ cells (macrophages/microglia) in the 
inflammatory infiltrate. There was a significant decline in the number of TCR + lymphocytes but no 
change in the number of CD11b/c+ cells. There was no change in the percentage of CD95 (Fas)+ or 
CD95 (Fas) ligand+ cells in the inflammatory infiltrate.  
  
3.3. Effect of a single dose of CsA on apoptosis 
In the total cell population, treatment with 4 mg/kg (on day 14) did not alter the percentage of cells that 
were apoptotic (data not shown). Treatment with CsA 8, 16 or 32 mg/kg (on day 15) produced a 
significant, dose-dependent increase in the number and percentage of cells that were apoptotic (Fig. 2). 
Table 4 shows the effects of CsA on apoptosis of cells labelled with different antibodies. Treatment 
with CsA 4 mg/kg did not alter the percentages or numbers of the different cell populations that were 
apoptotic. Treatment with CsA 8, 16 and 32 mg/kg caused a significant increase in the percentage of 
CD5+ cells undergoing apoptosis. There was increased apoptosis of TCR + cells after the 16 and 32 
mg/kg doses, although this was statistically significant only for the 16 mg/kg dose. CsA treatment did 
not alter the percentage of Fas+ or Fas ligand+ cells that were apoptotic. 
 Fig. 2. Number of cells per gram of spinal cord and percentage of the extracted cells that were apoptotic cells, in 
G0/G1 and G2/S/M phase on day 15 after treatment with saline or CsA 8, 16 or 32 mg/kg. In a dose-dependent 
fashion, there was a significant increase in the percentage of cells that were apoptotic after CsA treatment, and an 
increase in the number of apoptotic cells, although this was only significant for the highest dose of CsA. The 
increase in the percentage of cells that were apoptotic was accompanied by a decrease in the percentage of cells 
that were in G0/G1 phase.  
 
 
3.4. Effect of a single dose of CsA on selective apoptosis of V 8.2+ cells 
There was no significant change in the number or percentage of V 8.2+ cells that were apoptotic, after 
a single injection of CsA (Table 4). For each experiment, we calculated the ratio of the percentage of 
apoptotic cells that were V 8.2+ to the percentage of apoptotic cells that were TCR +, and the ratio 
of the percentage of non-apoptotic cells that were V 8.2+ to the percentage of non-apoptotic cells that 
were TCR +. The ratio of these two values was then calculated, and used to express the enrichment 
of V 8.2+ cells in the apoptotic T cell population compared to the non-apoptotic T cell population. 
Using this calculation, we have previously shown enrichment of V 8.2+ cells in the apoptotic T cell 
population in the CNS in MBP-EAE induced by the passive transfer of V 8.2+ MBP-reactive T cells, 
indicating selective apoptosis of V 8.2+ cells (Tabi et al., 1994). Similar selective apoptosis of V 8.2+ 
cells also occurs in the CNS in EAE induced by active immunization with MBP and adjuvants 
(McCombe et al., 1996a), the model used in the present study. We now show that CsA treatment 
decreases the enrichment of V 8.2+ cells in the apoptotic CD5+ and apoptotic TCR + lymphocyte 
populations (Fig. 3).  
 
Fig. 3. Ratios of the proportion of apoptotic CD5+ lymphocytes (upper panel) and apoptotic TCR + 
lymphocytes (lower panel) that are V 8.2+ to the proportion of non-apoptotic CD5+ lymphocytes and non-
apoptotic TCR + lymphocytes that are V 8.2+. This ratio gives an index of selective apoptosis of V 8.2+ cells. 
The ratio was reduced at all doses of CsA studied, although the results were statistically significant only for the 
TCR + populations (calculated by ANOVA; results that are significantly different from that of the saline-treated 
group (Tukey test) indicated by asterisks). The decrease was largely due to an increase in the percentages of CD5+ 
lymphocytes and TCR + lymphocytes that were apoptotic without an increase in the percentage of V 8.2+ cells 
that were apoptotic. 
4. Discussion 
We assessed the effects of CsA treatment on the clinical course of MBP-EAE in Lewis rats. Saline-
treated rats treated followed the usual clinical course of MBP-EAE (Pender, 1988). Treatment with 
high doses of CsA (16 and 32 mg/kg) caused suppression of the expected first episode of disease, with 
clinical signs of disease developing after treatment was ceased. Previously, CsA (50 mg/kg) has been 
shown to suppress EAE induced by inoculation of rats, guinea pigs and monkeys with bovine spinal 
cord, although some animals developed disease after treatment was ceased (Bolton et al., 1982). 
Treatment with CsA 4 mg/kg delayed the onset of the disease. Treatment with CsA 8 mg/kg delayed 
the onset of disease, increased the frequency of second episodes and resulted in 50% of rats having a 
third episode or following a chronic persistent course. This effect is similar to the effects of low-dose 
CsA treatment of EAE induced by inoculation with guinea pig spinal cord (Polman et al., 1988; Pender 
et al., 1990) and of experimental autoimmune neuritis (EAN) induced by inoculation with purified 
myelin (McCombe et al., 1990). However, the dose of CsA (8 mg/kg) required to cause relapses of 
MBP-EAE was higher than that (4 mg/kg) required to produce relapses of EAE induced with whole 
spinal cord. 
It is likely that the immunosuppressive actions of CsA (Hess et al., 1988) contribute to the suppression 
of signs of EAE. However, the ability of CsA to decrease blood–brain barrier permeability (Paul and 
Bolton, 1995) and the neuroprotective capacity of immunophilins (Sabatini et al., 1997) could also play 
a role. In earlier studies, Bolton et al. (1982) found that treatment with CsA 50 mg/kg caused a 
reduction in inflammation in the spinal cord of guinea pigs with EAE. In MBP-EAE, we now show that 
a single high dose of CsA (32 mg/kg) caused a decline in the percentage of TCR + cells in the spinal 
cord inflammatory infiltrate. This decline in the percentage of T cells in the spinal cord could result 
from decreased entry of cells to the CNS or increased removal from the CNS. 
To determine whether CsA treatment caused increased elimination of cells, we measured apoptosis. 
During spontaneous recovery from MBP-EAE, there is apoptosis of T cells (Pender et al., 1991 and 
Pender et al., 1992; Schmied et al., 1993) and macrophages/microglia in the CNS (Nguyen et al., 1994; 
White et al., 1998a). There is selective apoptosis of V 8.2+ MBP-reactive T cells(Tabi et al., 1994 and 
Tabi et al., 1995; McCombe et al., 1996a), which may be due to CD95-mediated antigen-specific 
activation-induced apoptosis (White et al., 1998b). Apoptosis of other cells in the CNS in EAE may be 
due to non-antigen-specific processes such as withdrawal of growth factors or the effects of 
endogenous corticosteroids (Pender et al., 1992; Nguyen et al., 1994). We now show that apoptosis of 
inflammatory cells in the spinal cord in MBP-EAE is increased 16 h after treatment with CsA. The 
percentages of CD5+ cells and TCR + cells that were apoptotic were increased. There was no 
increase in apoptosis of V 8.2+ T cells, the predominant encephalitogenic T cells in this form of EAE 
(Imrich et al., 1995). CsA treatment abrogated the selective apoptosis of V 8.2+ cells. We suggest that 
this indicates that CsA treatment leads to an increase in non-antigen-specific T cell apoptosis at the 
same time as decreasing antigen-specific activation-induced apoptosis of encephalitogenic T cells. 
The observed increase in total T cell apoptosis could be due to effects of CsA on non-antigen-specific 
apoptosis, for example by suppression of production of cytokines such as IL-2 that are necessary for 
cell survival. Another mechanism for increased T cell apoptosis is suggested by the finding that CsA 
can enhance transforming growth factor mediated apoptosis of lymphocytes (Andjelic et al., 1997). 
Our observation that CsA impairs the selective apoptosis of V 8.2+ T cells in the CNS may be 
explained by the known ability of CsA to reduce activation-induced apoptosis (Shi et al., 1989), by 
inhibiting the expression of Fas ligand (Brunner et al., 1996; Latinis et al., 1997). However, in the 
present study, we did not find a decline in expression of Fas or Fas ligand. 
Low-dose CsA may cause relapses of disease by suppressing a mechanism that normally prevents 
further episodes of disease. We have previously shown that corticosteroid treatment of MBP-EAE 
increases total T cell apoptosis but reduces apoptosis of V 8.2+ cells in the CNS, and leads to relapses 
of EAE (McCombe et al., 1996b; Nguyen et al., 1997). We therefore considered the possibility that 
CsA might induce relapses of disease by inhibiting the apoptosis of encephalitogenic T cells in the 
CNS. However, although we found that CsA treatment decreases the selective apoptosis of V 8.2+ 
cells, there was no decline in the percentage of V 8.2+ cells that were apoptotic. Another possible 
means by which CsA treatment could lead to relapses of EAE is by impairment of production of 
downregulatory cytokines. One possibility is IL-10 which is present in lower amounts in the spinal cord 
of DA rats, which follow a chronic course of MBP-EAE, compared to Lewis rats which have an acute 
course of disease (Diab et al., 1997). Further studies are required to determine whether alteration of 
cytokine production is related to the production of relapses in the present model of relapsing MBP-
EAE. In conclusion, the present study presents a model of chronic relapsing MBP-EAE in Lewis rats. It 
also shows that T cell apoptosis in the CNS in EAE can be modulated by the action of CsA.  
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